# Phase 2 Anemia, Sickle Cell trials recruiting: 27 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials in phase 2 for Anemia, Sickle Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Anemia, Sickle Cell trials: 27 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/anemia-sickle-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 1, 2026 | NCT07616154 | Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Sickle Cell Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616154) |
| January 27, 2026 | NCT07369024 | Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369024) |
| December 15, 2025 | NCT07282210 | Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype | Biossil Inc. | Phase 2 | Recruiting | Sickle Cell Disease, Sickle Cell Anaemia, Sickle Cell Anemia | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282210) |
| November 4, 2025 | NCT07224360 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | CSL Behring | Phase 2 | Recruiting | Sickle Cell Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224360) |
| September 16, 2025 | NCT07175051 | Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin | University of Illinois Chicago | Phase 2 | Recruiting | Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175051) |
| June 17, 2025 | NCT07023666 | Early Screening and Treatment of Heart Complication in Sickle Cell Disease | Inova Health Care Services | Phase 2 | Recruiting | Sickle Cell Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07023666) |
| March 12, 2025 | NCT06872333 | Allo HSCT for High Risk Hemoglobinopathies | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Graft Failure, Sickle Cell Disease, Hemoglobinopathies | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06872333) |
| November 21, 2024 | NCT06699849 | Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis | CSL Behring | Phase 2 | Recruiting | Sickle Cell Disease Vaso-occlusive Crisis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699849) |
| October 10, 2024 | NCT06635902 | Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Sickle Cell Disease, Vaso-occlusive Pain Episode | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06635902) |
| August 29, 2024 | NCT06578507 | Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell... | Theravia | Phase 2 | Recruiting | Sickle Cell Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578507) |
| April 10, 2024 | NCT06358638 | Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody | Children's National Research Institute | Phase 2 | Recruiting | Sickle Cell Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06358638) |
| February 15, 2024 | NCT06260891 | Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial | University of California, San Francisco | Phase 2 | Recruiting | Sickle Cell Disease | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06260891) |
| January 10, 2024 | NCT06198712 | A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease | Forma Therapeutics, Inc. | Phase 2 | Recruiting | Sickle Cell Disease | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06198712) |
| August 30, 2023 | NCT06016634 | Alendronate for Osteonecrosis in Adults With Sickle Cell Disease | University of California, Davis | Phase 2 | Recruiting | Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06016634) |
| July 20, 2023 | NCT05953584 | A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell... | Forma Therapeutics, Inc. | Phase 2 | Recruiting | Sickle Cell Disease | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05953584) |
| February 21, 2023 | NCT05736419 | A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Sickle Cell Disease, Thalassemia, Beta, Thalassemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05736419) |
| December 7, 2022 | NCT05640271 | Tocilizumab for Acute Chest Syndrome | University of Chicago | Phase 2 | Recruiting | Sickle Cell Disease, Acute Chest Syndrome | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05640271) |
| October 18, 2022 | NCT05583721 | Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Sickle Cell Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05583721) |
| August 29, 2022 | NCT05519111 | Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain | Icahn School of Medicine at Mount Sinai | Phase 2 | Recruiting | Sickle Cell Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05519111) |
| April 20, 2022 | NCT05336201 | Cognitive Remediation Intervention to Prepare for Transition of Care | University of Alabama at Birmingham | Phase 2 | Recruiting | Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05336201) |
| December 17, 2019 | NCT04201210 | A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD | University of Regensburg | Phase 2 | Recruiting | HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders, Sickling Disorder Due to Hemoglobin S... | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04201210) |
| September 23, 2019 | NCT04099966 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | Sponsor not shown (see the record) | Phase 2 | Recruiting | Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04099966) |
| July 16, 2018 | NCT03587272 | Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease | Sponsor not shown (see the record) | Phase 2 | Recruiting | Sickle Cell Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03587272) |
| July 11, 2017 | NCT03214354 | Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor | University of Calgary | Phase 2 | Recruiting | Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03214354) |
| April 19, 2017 | NCT03121001 | Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease | University of Illinois Chicago | Phase 2 | Recruiting | Sickle Cell Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03121001) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Illinois Chicago | 2 |
| [CSL Behring](https://specstream.ai/data/clinical-trials/company/csl-behring) | 2 |
| St. Jude Children's Research Hospital | 2 |
| Forma Therapeutics, Inc. | 2 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Theravia | 1 |
| Biossil Inc. | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| University of California, Davis | 1 |
| University of Alabama at Birmingham | 1 |
| University of Calgary | 1 |
| University of Regensburg | 1 |
| Children's National Research Institute | 1 |
| University of Chicago | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| New York Medical College | 1 |
| University of California, San Francisco | 1 |
| Inova Health Care Services | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 21 |
| Canada | 4 |
| France | 3 |
| Turkey (Türkiye) | 3 |
| United Kingdom | 3 |
| Nigeria | 2 |
| French Guiana | 1 |
| Belgium | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Austria | 1 |
| Germany | 1 |
| India | 1 |
| Oman | 1 |
| Kenya | 1 |
| Lebanon | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sake bars in the United States](https://specstream.ai/data/businesses/sake-bars/united-states)
- [Prosthodontics practices in the United States](https://specstream.ai/data/businesses/prosthodontics-practices/united-states)
- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/orthopedic-surgery-practices/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
- [Litigation law firms in the United States](https://specstream.ai/data/businesses/litigation-law-firms/united-states)
